CVSI — CV Sciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1510964 ·
Last close
$0.03
Market Cap
$5.85M
52W High
$0.10
52W Low
$0.03
ADV30
709,302
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,195,000 | 1,562,000 | -318,000 | -643,000 | 6,722,000 | 309,000 | 5,224,000 |
| Dec 2025 | 3,307,000 | 1,671,000 | -75,000 | -206,000 | 6,962,000 | 278,000 | 5,494,000 |
| Sep 2025 | 3,256,000 | 1,579,000 | -275,000 | -382,000 | 6,995,000 | 381,000 | 5,456,000 |
| Jun 2025 | 3,620,000 | 1,844,000 | -131,000 | -261,000 | 7,950,000 | 886,000 | 6,147,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-407,000
Investing CF
$-109,000
Financing CF
$337,000
CapEx
$-109,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-87,939,000
Inventory
$4,087,000
Receivables
$402,000
ST Investments
—
EBIT TTM
$-470,000
Pretax Income TTM
$-949,000
Interest Exp TTM
$481,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,789,000 | -470,000 | -958,000 | 6,962,000 | 5,494,000 | — | -407,000 |
| Dec 2024 | 15,705,000 | -2,190,000 | -2,394,000 | 7,927,000 | 6,132,000 | — | -861,000 |
| Dec 2023 | 16,004,000 | 3,360,000 | 3,102,000 | 9,200,000 | 6,297,000 | — | 2,253,000 |
| Dec 2022 | 16,205,000 | -6,847,000 | -8,214,000 | 12,736,000 | 13,513,000 | — | -1,885,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$27,025,000
NetIncome TTM
$-5,997,000
OpCashFlow TTM
$0
Assets (Latest)
$12,736,000
Forward EPS
$-0.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TCRT | Alaunos Therapeutics, Inc. | $5.98M | $2.45 | — |
| INM | InMed Pharmaceuticals Inc. | $5.70M | $1.72 | — |
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.63M | $2.38 | — |
| APVO | Aptevo Therapeutics Inc. | $6.09M | $4.89 | — |
| FBLG | FibroBiologics, Inc. | $5.52M | $1.06 | — |
News headlines (Yahoo Finance, 1h cache)
CV Sciences Inc (CVSI) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
2026-05-15 05:03 · Yahoo
CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results
2026-05-14 20:00 · Yahoo
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
2026-05-12 22:00 · Yahoo
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
2026-03-26 20:00 · Yahoo
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026
2026-03-24 21:00 · Yahoo
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
2026-03-10 21:00 · Yahoo
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
2026-02-26 13:30 · Yahoo
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
2025-12-23 00:00 · Yahoo
Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says
2025-12-13 16:15 · Yahoo
CV Sciences Inc (CVSI) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
2025-11-14 05:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.